# PLEURAL EFFUSION

## 病生理

• **Systemic factors** (eg, ↑ PCWP, ↓ oncotic pressure) → _transudative_ effusion

• **Local factors** (ie, Δ pleural surface permeability) → _exudative_ effusion

## Transudates

• **Congestive heart failure** (**40%**): 80% bilateral, ± cardiomegaly on CXR occasionally exudative (especially after aggressive diuresis or if chronic)

• **Constrictive pericarditis** (knock on exam, calcification or thickening on imaging)

• **Cirrhosis** (“hepatic hydrothorax”): diaphragmatic pores allow passage of ascitic fluid often right-sided (2/3) & massive (even without marked ascites)

• Nephrotic syndrome: usually small, bilateral, asymptomatic (排除 PE b/c hypercoag)

• Other: PE (usually exudate), malignancy (lymphatic obstruction), myxedema, CAPD

## Exudates

• **Lung parenchymal infection** (**25%**)

Bacterial (parapneumonic): can evolve along spectrum of _exudative_ (but sterile) → _fibropurulent_ (infected fluid) → _organization_ (fibrosis & formation of rigid pleural peel). Common causes: _Strep pneumo, Staph aureus, Strep milleri, Klebsiella, Pseudomonas, Haemophilus, Bacteroides, Peptostreptococcus_, mixed flora in aspiration pneumonia.

Mycobacterial: >50% lymphs 80% of the time, ADA >40, pleural bx ~70% Se

Fungal, viral (usually small), parasitic (eg, amebiasis, echinococcosis, paragonimiasis)

• **Malignancy** (**15%**): primary lung cancer most common, metastases (esp. breast, lymphoma, etc.), mesothelioma (✔ serum osteopontin levels; _NEJM_ 2005;353:15)

• **Pulmonary embolism** (**10%**): effusions in ~40% of PEs; exudate (75%) > transudate (25%); hemorrhagic—_must have high suspicion b/c presentation highly variable_

• **Collagen vascular disease:** RA (large), SLE (small), GPA, EGPA

• **Abdominal diseases:** pancreatitis, cholecystitis, esophageal rupture, abdominal abscess

• Hemothorax (Hcteff/Hctblood >50%): trauma, PE, malignancy, coagulopathy, leaking aortic aneurysm, aortic dissection, pulmonary vascular malformation

• Chylothorax (triglycerides >110): thoracic duct damage due to trauma, malignancy, LAM

• Other:

Post-CABG: left-sided; initially bloody, clears after several wks

Dressler’s syndrome (pericarditis & pleuritis post-MI), uremia, post-radiation therapy

Asbestos exposure: benign; ⊕ eosinophils

Drug-induced (eg, nitrofurantoin, methysergide, bromocriptine, amiodarone): ⊕ eos

Uremia; post-XRT; sarcoidosis

Meigs’ syndrome: benign ovarian tumor → ascites & pleural effusion

Yellow-nail syndrome: yellow nails, lymphedema, pleural effusion, bronchiectasis

## Diagnostic studies (_NEJM_ 2018;378:740)

• **Thoracentesis (ideally U/S guided)** (_NEJM_ 2006;355:e16)

_Indications:_ **all effusions** >**1 cm in decubitus view**

if suspect due to CHF, can diurese and see if effusions resolve (75% do so in 48 h); _asymmetry, fever_, _chest pain or failure to resolve_ → thoracentesis

### parapneumonic effusions should be tapped as soon as possible (_cannot_ exclude infxn clinically)

_Diagnostic studies:_ ✔ total protein, LDH, glucose, cell count with differential, Gram stain & culture, pH; remaining fluid for additional studies as dictated by 臨床scenario

_Complications:_ PTX (5–10%), hemothorax (~1%), re-expansion pulm edema (if >1.5 L removed), spleen/liver lac.; post-tap CXR not routinely needed (_Annals_ 1996;124:816)

↓ PTX with U/S and experienced supervisor; even with INR ~1.9, risk of bleed low with U/S & experienced operator (_Chest_ 2009;135:1315 & 2013;144:456; _Archives_ 2010;170:332)

• **Transudate vs. exudate** (_JAMA_ 2014;311:2422)

**Light’s criteria:** exudate = TPeff/TPserum >0.5 _or_ LDHeff/LDHserum >0.6 _or_ LDHeff >2/3 ULN of LDHserum; 97% Se, 85% Sp; best Se of all methods; however, will misidentify 25% of transudates as exudates; ∴ if clinically suspect transudate but meets criterion for exudate, confirm with test with higher Sp

Exudative criteria with better Sp: choleff >55 mg/dL (95–99% Sp); choleff >45 mg/dL _and_ LDHeff >200 (98% Sp); choleff/cholserum >0.3 (94% Sp); serum-effusion alb gradient ≤1.2 (92% Sp); serum-effusion TP gradient ≤3.1 (91% Sp)

CHF effusions: _TP may_ ↑ _with diuresis or chronicity_ → “pseudoexudate”; alb gradient ≤1.2, choleff >60 mg/dL (Se 54%, Sp 92%) or clin judgment to distinguish (_Chest_ 2002;122:1524)

• **Complicated vs. uncomplicated parapneumonic** (_Chest_ 1995;108:299)

complicated = ⊕ Gram stain or culture _or_ pH <7.2 _or_ glucose <60

complicated parapneumonic effusions usually require tube thoracostomy for resolution

empyema = frank pus, also needs tube thoracostomy (_J Thorac CV Surg_ 2017;153:e129)

• Additional pleural fluid studies (_NEJM_ 2002;346:1971)

NT-proBNP ≥1500 pg/mL has 91% Se & 93% Sp for CHF (_Am J Med_ 2004;116:417)

WBC & diff.: exudates tend to have ↑ WBC vs. transudates but nonspecific neutrophils → parapneumonic, PE, pancreatitis lymphocytes (>50%) → cancer, TB, rheumatologic eos (>10%) → blood, air, drug rxn, asbestos, paragonimiasis, Churg-Strauss, PE

RBC: Hcteff 1–20% → cancer, PE, trauma; Hcteff/Hctblood >50% → hemothorax

AFB: yield in TB 0–10% with stain, 11–50% with culture, ~70% with pleural bx

adenosine deaminase (ADA): seen with granulomas, >70 suggests TB, <40 excludes TB

cytology: ideally ≥150 mL and at least 60 mL should be obtained (_Chest_ 2010;137:68)

glucose: <60 mg/dL → malignancy, infection, RA

amylase: seen in pancreatic disease and esophageal rupture (salivary amylase)

rheumatoid factor, CH50, ANA: _limited utility_ in dx collagen vascular disease

triglycerides: >110 → chylothorax, 50–110 → ✔ lipoprotein analysis for chylomicrons

cholesterol: >60; seen in chronic effusions (eg, CHF, RA, old TB)

creatinine: effusion/serum ratio >1 → urinothorax

fibulin-3: ↑ plasma and/or effusion levels → mesothelioma (_NEJM_ 2012;367:1417)

• Chest CT; pleural biopsy; VATS

• Undiagnosed persistent pleural effusions (_Clin Chest Med_ 2006;27:309)

_Transudative:_ most commonly CHF or hepatic hydrothorax. ✔ signs and symptoms CHF or cirrhosis, NT-proBNPeff; consider intraperitoneal injection of technetium-99m sulfur colloid

_Exudative_ (ensure using Sp test listed above): most commonly malig, empyema, TB, PE. ✔ signs and symptoms malig, chest CT (I+), ADA or IFN-γ release assay; consider thoracoscopy.

![](https://i.imgur.com/7etkXF1.jpg)

## 治療

• Symptomatic effusion: therapeutic thoracentesis, treat underlying disease process

• Parapneumonic effusion (_Chest_ 2000;118:1158)

uncomplicated → antibiotics for pneumonia

\>½ **hemithorax _or_ complicated _or_ empyema** → **tube thoracostomy** (otherwise risk of organization and subsequent need for surgical decortication)

loculated→ tube thoracostomy or VATS; intrapleural t-PA + DNase ↓ need for surgical referral (_NEJM_ 2011;365:518)

• Malignant effusion: serial thoracenteses vs. tube thoracostomy + pleurodesis (success rate ~80–90%) vs. indwelling pleural catheter, which ↓ hosp days but ↑ adverse events (_JAMA_ 2017;318:1903); systemic steroids & pH <7.2 a/w ↑ pleurodesis failure rate

• TB effusions: effusion will often resolve spontaneously; however, treat Pt for active TB

• Hepatic hydrothorax

Rx: Δ pressure gradient (ie, ↓ ascitic fluid volume, NIPPV)

avoid chest tubes; prn thoracenteses, pleurodesis, TIPS or VATS closure of diaphragmatic defects if medical Rx fails; NIPPV for acute short-term management

spontaneous bacterial empyema (SBEM) can occur (even without SBP being present), ∴ thoracentesis if suspect infection

transplant is definitive 治療 and workup should begin immediately
